Diabetes Drugs and Diagnostics Market is Expected to Reach US$ 134.0 Billion by 2032 - IMARC Group

The latest report by IMARC Group, titled "𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐃𝐫𝐮𝐠𝐬 𝐚𝐧𝐝 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐛𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭 (𝐎𝐫𝐚𝐥 𝐀𝐧𝐭𝐢𝐝𝐢𝐚𝐛𝐞𝐭𝐢𝐜𝐬, 𝐈𝐧𝐬𝐮𝐥𝐢𝐧, 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬), 𝐚𝐧𝐝 𝐑𝐞𝐠𝐢𝐨𝐧 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐", The global diabetes drugs and diagnostics market size reached US$ 74.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 134.0 Billion by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032.

𝐅𝐚𝐜𝐭𝐨𝐫𝐬 𝐀𝐟𝐟𝐞𝐜𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐫𝐨𝐰𝐭𝐡 𝐨𝐟 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐃𝐫𝐮𝐠𝐬 𝐚𝐧𝐝 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲:

𝐑𝐢𝐬𝐢𝐧𝐠 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬:
The global diabetes drugs and diagnostics market is experiencing significant growth due to the alarming rise in diabetes prevalence worldwide. Diabetes has reached epidemic proportions, with millions of individuals diagnosed each year. This consumer is primarily attributed to unhealthy lifestyles, including sedentary behavior and poor dietary choices. Moreover, increased awareness about the importance of early diabetes detection and management has led to higher demand for diagnostics tools and medications. This factor is driving market growth as pharmaceutical companies and diagnostic device manufacturers strive to meet this growing demand. It also emphasizes the need for continuous research and development to introduce innovative products for effective diabetes management.

𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬:
Another driving force behind the global diabetes drugs and diagnostics market is the continuous advancement in diagnostic technologies. The development of more accurate, rapid, and user-friendly glucose monitoring devices, such as continuous glucose monitors (CGMs) and flash glucose monitoring systems, has transformed diabetes management. These innovations provide real-time data to patients and healthcare professionals, enabling better glycemic control. Additionally, the integration of artificial intelligence (AI) and machine learning in diabetes diagnostics has enhanced predictive capabilities, leading to early intervention and personalized treatment plans. These technological advancements improve patient outcomes and also create opportunities for companies to expand their product portfolios, thus boosting market growth.

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭:
Investment in research and development (R&D) plays a crucial role in driving the diabetes drugs and diagnostics market. Pharmaceutical companies and diagnostic device manufacturers are dedicating substantial resources to develop novel drug therapies and diagnostic tools. The focus is on improving treatment efficacy and patient convenience. This includes the development of insulin analogs, oral antidiabetic drugs, and minimally invasive diagnostic devices. Government initiatives and funding support for diabetes-related R&D further accelerate innovation in the field. As companies continue to invest in cutting-edge technologies and explore new treatment modalities, the market is expected to witness sustained growth.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐰𝐢𝐭𝐡 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫:
Abbott Laboratories
AstraZeneca plc
B. Braun Medical Ltd.
Dexcom, Inc
Eli Lilly and Company
Insulet Corporation
Janssen Pharmaceuticals Inc. (Johnson & Johnson)
LifeScan IP Holdings, LLC
Medtronic plc
Merck & Co. Inc.
Novo Nordisk A/S
Roche Diabetes Care, Inc (F. Hoffmann-La Roche AG)
Sanofi-Aventis U.S. LLC (Sanofi S.A.)

𝐅𝐨𝐫 𝐚𝐧 𝐢𝐧-𝐝𝐞𝐩𝐭𝐡 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬, 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐫𝐞𝐟𝐞𝐫 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: https://www.imarcgroup.com/diabetes-drugs-diagnostics-market/requestsample

𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:
𝐓𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐡𝐚𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐟𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐜𝐚𝐭𝐞𝐠𝐨𝐫𝐢𝐞𝐬:

𝐁𝐫𝐞𝐚𝐤𝐮𝐩 𝐛𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭:
Oral Antidiabetics
Breakup by Class
Biguanides
Alpha-Glucosidase Inhibitors
Sodium-Glucose Cotransport -2 Inhibitors (SGLT-2 Inhibitors)
Dipeptidyl Peptidase-4 Inhibitors (DPP-4 Inhibitors)
Sulfonylureas
Dopamine -D2 Receptor Agonist
Others
Insulin
Breakup by Class
Long Acting Insulin
Fast Acting Insulin
Short Acting
Others
Diabetes Diagnostics
Breakup by Product Type
Blood Glucose Meters
Blood Glucose Strips
Lancets
Breakup by End-User
Hospitals and Clinics
Home Healthcare
Ambulatory Care Centers
Others
Based on the segment, the market has been divided into, oral antidiabetics (breakup by class (Biguanides, Alpha-Glucosidase Inhibitors, Sodium-Glucose Cotransport -2 Inhibitors (SGLT-2 Inhibitors), Dipeptidyl Peptidase-4 Inhibitors (DPP-4 Inhibitors), Sulfonylureas, Dopamine -D2 Receptor Agonist, Others)), insulin (breakup by class (Long Acting Insulin, Fast Acting Insulin, Short Acting, Others)),  Diabetes Diagnostics (Breakup by Product Type (Blood Glucose Meter, Blood Glucose Strips, Lancets) Breakup by End-User (Hospitals and Clinics, Home Healthcare, Ambulatory Care Centers, Others).

𝐀𝐬𝐤 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.imarcgroup.com/request?type=report&id=2034&flag=C

𝐌𝐚𝐫𝐤𝐞𝐭 𝐁𝐫𝐞𝐚𝐤𝐮𝐩 𝐛𝐲 𝐑𝐞𝐠𝐢𝐨𝐧:
North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa
North America's dominance in the market is attributed to its high healthcare spending, a significant prevalence of diabetes, and a robust healthcare infrastructure that supports the demand for diabetes drugs and diagnostics.

𝐆𝐥𝐨𝐛𝐚𝐥 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐃𝐫𝐮𝐠𝐬 𝐚𝐧𝐝 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬:
The aging population and rapid urbanization are significant drivers of the diabetes market. Aging individuals are more prone to diabetes, and as the global population ages, the demand for diabetes management solutions increases. Moreover, urbanization often leads to sedentary lifestyles and unhealthy dietary habits, further contributing to the rise in diabetes cases. This demographic shift creates a sustained market demand for diabetes drugs and diagnostics. Additionally, changes in healthcare policies and increased insurance coverage for diabetes-related services have a positive impact on the market. Many governments and healthcare systems worldwide have recognized the economic burden of diabetes and have taken steps to improve access to diabetes medications and diagnostic tools. This enhanced coverage encourages individuals to seek early diagnosis and treatment, thereby driving market growth.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
https://imarcreport.notion.site/Vital-Signs-Monitoring-Devices-Market-Overview-2024-2032-Demand-by-Regions-Types-and-Analysis-of-K-614f228aef5e422e942cfc5f47765d55?pvs=4
https://imarcreport.notion.site/Smart-Stadium-Market-Overview-2023-2028-Demand-by-Regions-Types-and-Analysis-of-Key-Players-5c6554ac0da647808dc74c69fd0afb6d?pvs=4
https://imarcreport.notion.site/Managed-Print-Services-Market-Overview-2023-2028-Demand-by-Regions-Types-and-Analysis-of-Key-Playe-970ad144ae9947f3947f483a3fc2eae8?pvs=4
https://imarcreport.notion.site/Seed-Coating-Market-Report-2024-Industry-Trends-Growth-Size-and-Forecast-Till-2032-0ab0b7b6b72344ae8267a181e8dfbc01?pvs=4
https://imarcreport.notion.site/Poultry-Diagnostics-Market-Report-2023-Size-Share-Growth-Demand-And-Forecast-Till-2028-38a1e3d1e413407b81d34521a7233183?pvs=4
https://imarcreport.notion.site/Packaging-Tapes-Market-Report-2024-Size-Share-Growth-Demand-And-Forecast-Till-2032-d18cf0bf30ef4ac1abef68e97b9da2db?pvs=4

𝐍𝐨𝐭𝐞: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA 
Follow us on Twitter: @imarcglobal

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.